Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Nov 2013

Barone Giuseppe, Anderson John, Pearson Andrew D J, Petrie Kevin, Chesler Louis

Abstract excerpt

Clinical outcome remains poor in patients with high-risk neuroblastoma, in which chemoresistant relapse is common following high-intensity conventional multimodal therapy. Novel treatment approaches are required. Although recent genomic profiling initiatives have not revealed a high frequency of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Enzyme Activation
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to N-Myc Proto-Oncogene Protein

Share to Neuroblastoma

Share to Oncogene Proteins

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 23965898
DOI: 10.1158/1078-0432.CCR-13-0680
PMCID: PMC3818140

Genes

MYCN
ALK
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23965898-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.PMID 23965898Read ↗

ALK Inhibitors in Neuroblastoma: A Sprint from Bench to Bedside.Semantic proximity Read ↗

Targeting anaplastic lymphoma kinase in neuroblastomaSemantic proximity Read ↗

ALK in Neuroblastoma: Biological and Therapeutic ImplicationsSemantic proximity Read ↗

Targeted Therapy for Neuroblastoma: ALK InhibitorsSemantic proximity Read ↗

Neuroblastoma treatment in the post-genomic eraSemantic proximity Read ↗

COMBINATION THERAPIES TARGETING ALK-ABERRANT NEUROBLASTOMA IN PRECLINICAL MODELSSemantic proximity Read ↗

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy CombinationSemantic proximity Read ↗

Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterationsSemantic proximity Read ↗

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastomaSemantic proximity Read ↗

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumorsSemantic proximity Read ↗

Neuroblastoma and MYCN.Semantic proximity Read ↗

Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft modelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.